Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China.
2 The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
J Tradit Chin Med. 2022 Aug;42(4):604-610. doi: 10.19852/j.cnki.jtcm.20220617.003.
To investigate the short-term efficacy and safety outcomes following a sequential treatment with clearing heat and eliminating phlegm (CHEP) formula and tonifying Qi and activating blood circulation (TQABC) formula in patients with acute ischemic stroke (AIS) within a 72 h time window.
In this randomized, multicenter, double-blinded, placebo-controlled trial, 500 participants will be randomly assigned in a ratio of 1∶1 to the CHEP+ TQABC group or control group. In addition to guideline-based standard medical care, participants in the treatment group will receive the CHEP formula for the first 5 consecutive days followed by the TQABC formula for another 10 consecutive days, while those in the control group will receive CHEP formula placebo and TQABC formula placebo consecutively. The primary outcome measure will be the comparison of the change in the National Institutes of Health Stroke Scale score from baseline to 15 days after randomization. The secondary outcome measures will include the scores on the modified Rankin Scale, Barthel Index, Patient-Reported Outcomes, TCM symptom pattern (Zheng-hou) evaluation Scale, and the incidence of in-hospital complications. Safety assessment will include the physical examination, laboratory detection, any adverse events or serious adverse events, and the proportion of any complications during hospitalization.
The results of this study will provide objective and scientific data with which to assess the efficacy and safety of a sequential treatment based on "integrating disease and symptom pattern" for patients with AIS.
在 72 小时时间窗内,观察清热化痰(CHEP)方序贯益气活血(TQABC)方治疗急性缺血性脑卒中(AIS)患者的短期疗效和安全性结局。
这是一项随机、多中心、双盲、安慰剂对照试验,将 500 名参与者按照 1∶1 的比例随机分配至 CHEP+TQABC 组或对照组。除了基于指南的标准医疗护理外,治疗组的参与者将在第 1 至第 5 天连续接受 CHEP 配方,然后在第 6 至第 15 天连续接受 TQABC 配方,而对照组将连续接受 CHEP 配方安慰剂和 TQABC 配方安慰剂。主要结局指标是从随机分组到 15 天的 NIHSS 评分变化的比较。次要结局指标包括改良 Rankin 量表、Barthel 指数、患者报告的结局、中医症状模式(证侯)评价量表和住院期间并发症的发生率。安全性评估将包括体格检查、实验室检测、任何不良事件或严重不良事件,以及住院期间任何并发症的比例。
该研究的结果将提供客观和科学的数据,以评估基于“整合疾病与症状模式”的序贯治疗对 AIS 患者的疗效和安全性。